Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Januar 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.3k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • J Offline
    J Offline
    JKY_VH
    wrote on sidst redigeret af
    #86

    Vil nu foretrække at den kommer nu

    1 Reply Last reply
    0
    • B Offline
      B Offline
      bibob
      wrote on sidst redigeret af
      #87

      Enig JKY. - bare for at få lidt ro på.

      1 Reply Last reply
      0
      • T Offline
        T Offline
        transalp
        wrote on sidst redigeret af
        #88

        Go morgen.. 🙂

        1 Reply Last reply
        0
        • Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktør
          wrote on sidst redigeret af
          #89

          God morgen. 🙂

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #90

            Daratumumab Plus Rd Sustains Responses in Transplant-Ineligible Myeloma https://www.targetedonc.com/news/daratumumab-plus-rd-sustains-responses-in-transplantineligible-myeloma

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #91

              "Bahlis: The combination of anti-CD38 antibody, specifically daratumumab, with dexamethasone represents a new standard...... This represents a novel frontline therapy that can become the standard to compare to."

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #92

                "....but we are looking at the possibility of re-treatment of daratumumab at this meeting. The concept of the LYNCH trial, which is looking at retreatment of daratumumab at the time of relapse or disease-progression in combination with carfilzomib. While we are going to use daratumumab in the frontline setting, we hope a future study will demonstrate that daratumumab can be reused in the subsequent lines of therapy as well."

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  bibob
                  wrote on sidst redigeret af
                  #93

                  God morgen. 🙂

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #94

                    https://www.lifescienceleader.com/doc/the-step-strategy-that-saved-genmab-from-a-dire-outlook-0001 Lidt weekend læsning.

                    1 Reply Last reply
                    0
                    • SolsenS Offline
                      SolsenS Offline
                      Solsen
                      wrote on sidst redigeret af
                      #95

                      https://www.lifescienceleader.com/doc/current-issue-table-of-contents-0003 Ovenstående fra dette tidsskrift...

                      1 Reply Last reply
                      0
                      • K Offline
                        K Offline
                        kkjoel
                        wrote on sidst redigeret af
                        #96

                        Wow, for en artikel 🙂 Genmab forklaret på 10 min 😉

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          GeorgeBest
                          wrote on sidst redigeret af
                          #97

                          Rajkumar not impressed with Revlimid Price hike https://twitter.com/vincentrk/status/1213124615922475008?s=21

                          1 Reply Last reply
                          0
                          • B Offline
                            B Offline
                            bibob
                            wrote on sidst redigeret af
                            #98

                            God morgen. Og god søndag til alle. 🙂

                            1 Reply Last reply
                            0
                            • Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktør
                              wrote on sidst redigeret af
                              #99

                              God morgen. 🙂

                              1 Reply Last reply
                              0
                              • J Offline
                                J Offline
                                JKY_VH
                                wrote on sidst redigeret af
                                #100

                                God formiddag og tak ilm bibob:-)

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #101

                                  Monoclonal antibody-based quadruplet regimen with daratumumab, carfilzomib, lenalidomide, and dexamethasone with MRD–based response-adapted therapy in patients with newly diagnosed MMhttps://multiplemyelomahub.com/medical-information/monoclonal-antibody-based-quadruplet-regimen-with-daratumumab-carfilzomib-lenalidomide-and-dexamethasone-with-mrd-based-response-adapted-therapy-in-patients-with-newly-diagnosed-mm

                                  1 Reply Last reply
                                  0
                                  • StockBullS Offline
                                    StockBullS Offline
                                    StockBull
                                    wrote on sidst redigeret af
                                    #102

                                    Morn 🙂 TA begynder et se interessandt ud efter min mening. Ligger p.t i støtteområde og tæt på bunden i det opadgående trendkanal fra Okt. 2018. Retracement burde snart være et overstået kapitel og stigning op mod/over 1700 ligger i kortene så krydret med lidt godt positivt burde der snart ske noget

                                    1 Reply Last reply
                                    0
                                    • Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktør
                                      wrote on sidst redigeret af
                                      #103

                                      God morgen. 🙂

                                      1 Reply Last reply
                                      0
                                      • D Offline
                                        D Offline
                                        Doublo
                                        wrote on sidst redigeret af
                                        #104

                                        God morgen en god nyhed at starte dagen med
                                        Pandora A/SRealtidskurs
                                        Forandring
                                        0%Senest0,00 DKK
                                        Køb
                                        Sælg
                                        Læs mere
                                        GENMAB/JP MORGAN: LØFTER KURSMÅL TIL 1700 KR. OG GENTAGER OVERVÆGT

                                        07:19
                                        JP Morgan løfter kursmålet for aktien i Genmab til 1700 kr. fra 1500 kr.

                                        Det fremgår af data fra Bloomberg News.

                                        Finanshuset gentager aktieanbefalingen overvægt.

                                        Genmab-aktien faldt 2,8 pct. til 1444,50 kr. fredag.

                                        /ritzau/FINANS

                                        Claus Mikkelsen
                                        © RITZAU

                                        1 Reply Last reply
                                        0
                                        • Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktør
                                          wrote on sidst redigeret af
                                          #105

                                          Tusinde tak Duoblo. 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger